Basic information Synthesis Safety Related Supplier

ChemicalBook Product Catalog API Fluid, Electrolyte, and Acid-Base Balance Electrolyte Balance Pharmacology Etidronic acid

1/1

Etidronic acid NEW

$ 31.00 /500mg

Min. Order
Purity96.73%
Cas No2809-21-4
Supply Ability10g
Update time2025-04-28

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP4Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Etidronic acid
CAS No	2809-21-4
EC-No
Min. Order
Purity	96.73%
Supply Ability	10g
Release date	2025/04/28

Product Introduction

Bioactivity

Name	Etidronic acid
Description	Etidronic acid (HEDP) is a diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
In vitro	Etidronate inhibits directly osteoclastic bone-resorbing activity by pit assay. Etidronate also directly induces apoptosis and disrupts actin rings in osteoclasts. [1]
In vivo	Etidronate, when administered s.c. repeatedly at 10 or 40 mg/kg/day, gradually suppresses the adjuvant-induced allodynia In the rats with adjuvant arthritis, as assessed by 10-g von Frey hair. Etidronate (10-40 mg/kg/day) suppresses the adjuvant-induced mechanical allodynia in rat hindpaw. Etidronate (5–10 mg/kg/day) dose-dependently prevents the decrease in bone mineral density (BMD) in the proximal tibia of the arthritic rats. [2] Etidronate inhibits the histidine decarboxylase induction, but not the other inflammatory reactions induced by alendronate. Etidronate (unlike clodronate) also inhibits alendronate-induced BP-line formation in mice (even at 40 mmol/kg). Etidronate (160 mmol/kg) also inhibits the physicochemical changes in the tibia induced by six, weekly injections of alendronate. [3] Etidronate (10 mg/kg) combined with Calcitriol after subtotal nephrectomy (SNx) significantly inhibits thoracic and abdominal aortic calcification 3 weeks after the operation in rats. [4] Etidronate (5 mg/kg or 10 mg/kg) significantly reduces the thoracic and abdominal aortic calcification induced by calcitriol in the renal failure rat. Etidronate (5 mg/kg or 10 mg/kg) also reduces the dysfunction in aortic contraction. Etidronate (5 mg/kg) reverses the reduction in the aortic expression of matrix Gla protein mRNA observed in nephrectomized rats. [5]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 45 mg/mL (218.41 mM), Sonication is recommended.
Keywords	V-type proton ATPase catalytic subunit \| protein tyrosine phosphatase(PTP) \| Paget's disease \| osteoporosis \| MCF-7 \| Inhibitor \| inhibit \| HAP \| Etidronic acid \| arterial calcification \| Apoptosis
Inhibitors Related	Stavudine \| 5-Fluorouracil \| Acetylcysteine \| Dextran sulfate sodium salt (MW 4500-5500) \| Sodium 4-phenylbutyrate \| L-Ascorbic acid \| L-Glutamic acid \| Metronidazole \| Tributyrin \| Stearic acid \| L-Ascorbic acid sodium salt \| Salicylic acid
Related Compound Libraries	Pain-Related Compound Library \| Bioactive Compound Library \| Anti-Cancer Clinical Compound Library \| Drug Repurposing Compound Library \| Anti-Viral Compound Library \| Inhibitor Library \| FDA-Approved Drug Library \| Anti-Cancer Approved Drug Library \| Cosmetic Ingredient Compound Library \| Immunology/Inflammation Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Active Compound Library

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy